107 related articles for article (PubMed ID: 10669173)
1. Further evidence that activated protein C resistance affects protein C coagulant activity assays.
Jennings I; Kitchen S; Cooper PC; Rimmer JE; Woods TA; Preston FE
Thromb Haemost; 2000 Jan; 83(1):171-2. PubMed ID: 10669173
[No Abstract] [Full Text] [Related]
2. Evaluation of smoking as a risk factor for activated protein C resistance during pregnancy.
Kafkas S; Kalkan U; Bolaman Z; Sanci M; Yüksel H; Odabaşi AR
Gynecol Obstet Invest; 2007; 64(2):89-94. PubMed ID: 17314487
[TBL] [Abstract][Full Text] [Related]
3. [Clinical usefulness of global assays of the anticoagulant pathway of protein C].
Toulon P
Ann Biol Clin (Paris); 2001; 59(5):545-50. PubMed ID: 11602384
[TBL] [Abstract][Full Text] [Related]
4. Haemostatic changes and acquired activated protein C resistance in normal pregnancy.
Mahieu B; Jacobs N; Mahieu S; Naelaerts K; Vertessen F; Weyler J; Jacquemyn Y; Van der Planken M
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):685-8. PubMed ID: 17890957
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
Gessoni G; Valverde S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
[TBL] [Abstract][Full Text] [Related]
6. Children with Legg-Perthes diseases.
Pokharel RK; Matsuo M; Shiba R; Fujii S
Clin Orthop Relat Res; 1999 Jun; (363):268-9. PubMed ID: 10379332
[No Abstract] [Full Text] [Related]
7. Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study.
El-Karaksy H; El-Koofy N; El-Hawary M; Mostafa A; Aziz M; El-Shabrawi M; Mohsen NA; Kotb M; El-Raziky M; El-Sonoon MA; A-Kader H
Ann Hematol; 2004 Nov; 83(11):712-5. PubMed ID: 15309526
[TBL] [Abstract][Full Text] [Related]
8. Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease.
Payzin B; Adakan FY; Yalçin HC; Cetinkaya GS; Berkmen S; Eraslan S; Unsal B
Turk J Gastroenterol; 2006 Sep; 17(3):183-90. PubMed ID: 16941251
[TBL] [Abstract][Full Text] [Related]
9. Measurement of activated protein C resistance during menstrual cycle in women with and without the Leiden mutation.
Wramsby ML; Bremme K; Blombäck M
Thromb Haemost; 2001 Apr; 85(4):614-8. PubMed ID: 11341494
[TBL] [Abstract][Full Text] [Related]
10. A 2-year retrospective analysis of laboratory testing for activated protein C resistance with a factor V-corrected activated partial thromboplastin time-based method.
De Bel AV; Van der Cruyssen GA; Devreese KM
Blood Coagul Fibrinolysis; 2006 Mar; 17(2):155-60. PubMed ID: 16479199
[TBL] [Abstract][Full Text] [Related]
11. Intraindividual consistency of the activated protein C resistance phenotype.
Tosetto A; Simioni M; Madeo D; Rodeghiero F
Br J Haematol; 2004 Aug; 126(3):405-9. PubMed ID: 15257714
[TBL] [Abstract][Full Text] [Related]
12. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
Graf LL; Welsh CH; Qamar Z; Marlar RA
Am J Clin Pathol; 2003 Jan; 119(1):52-60. PubMed ID: 12520697
[TBL] [Abstract][Full Text] [Related]
13. Screening with the activated protein C resistance assay yields significant savings in a patient population with low prevalence of factor V leiden.
Taylor LJ; Oster RA; Fritsma GA; Tichenor PH; Reed CE; Eiland BM; Hudson CL; Marques MB
Am J Clin Pathol; 2008 Mar; 129(3):494-9. PubMed ID: 18285275
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of activated protein C resistance phenotype in subjects with compound heterozygosity for HR2 haplotype and FV Leiden mutation (R506Q) in factor V gene.
Castaman G; Ruggeri M; Tosetto A; Rodeghiero F
Thromb Haemost; 2000 Aug; 84(2):357-8. PubMed ID: 10959717
[No Abstract] [Full Text] [Related]
15. Activated protein C resistance in the Japanese population due to homozygosity for the factor V R2 haplotype.
Okada H; Toyoda Y; Takagi A; Saito H; Kojima T; Yamazaki T
Int J Hematol; 2010 Apr; 91(3):549-50. PubMed ID: 20300981
[No Abstract] [Full Text] [Related]
16. Learning from peer assessment: the role of the external quality assurance multilaboratory thrombophilia test process.
Favaloro EJ
Semin Thromb Hemost; 2005 Feb; 31(1):85-9. PubMed ID: 15706479
[TBL] [Abstract][Full Text] [Related]
17. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology.
Favaloro EJ; Bonar R; Sioufi J; Wheeler M; Low J; Aboud M; Duncan E; Smith J; Exner T; Lloyd J; Marsden K;
Semin Thromb Hemost; 2005 Feb; 31(1):49-58. PubMed ID: 15706475
[TBL] [Abstract][Full Text] [Related]
18. Activated protein C resistance: the commonest hereditary hypercoagulation disorder.
Khogali I; Summerfield GP; Mudawi A
Br J Surg; 1998 Aug; 85(8):1160; author reply 1161. PubMed ID: 9718028
[No Abstract] [Full Text] [Related]
19. [A novel assay for detecting the thrombomodulin-protein C/S anticoagulant pathway using human thrombomodulin (prothrombinase assay)].
Mohri M; Sata M; Gomi K; Maruyama Y; Osame M; Maruyama I
Rinsho Byori; 1997 Feb; Suppl 104():203-4. PubMed ID: 9128383
[No Abstract] [Full Text] [Related]
20. Testing for hypercoagulable disorders.
Ghobrial MW; Kwakwa H
Arch Intern Med; 2002 Mar; 162(5):613; author reply 614. PubMed ID: 11871941
[No Abstract] [Full Text] [Related]
[Next] [New Search]
